Literature DB >> 23990574

The DISCUSS Project: induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: points to consider.

Geoffrey P Lomax1, Sara Chandros Hull, Justin Lowenthal, Mahendra Rao, Rosario Isasi.   

Abstract

Human somatic cell reprogramming is a leading technology for accelerating disease modeling and drug discovery. Research organizations are sponsoring initiatives to create libraries of induced pluripotent stem cell (iPSC) lines for broad distribution and application. Donor informed consent plays a critical role in supporting the ethical conduct of iPSC research. To date, our organizations have focused on informed consent considerations for somatic cell collection intended specifically for iPSC derivation and distribution. This article considers how somatic cells obtained under general (biomedical) research protocols can be used for iPSC derivation. We present draft Points to Consider regarding the use of human somatic cells for iPSC research. Our goal is to initiate a process designed to develop consensus for the use of previously collected specimens for iPSC research. We anticipate publishing final considerations in early 2014.

Entities:  

Mesh:

Year:  2013        PMID: 23990574      PMCID: PMC3785257          DOI: 10.5966/sctm.2013-0099

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  7 in total

1.  Governing stem cell banks and registries: emerging issues.

Authors:  Rosario M Isasi; Bartha M Knoppers
Journal:  Stem Cell Res       Date:  2009-05-25       Impact factor: 2.020

2.  Stem cell policy exceptionalism: proceed with caution.

Authors:  Geoffrey P Lomax; Steven R Peckman
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

Review 3.  Sustained interaction: the new normal for stem cell repositories?

Authors:  Rosario Isasi; Bartha M Knoppers; Geoffrey Lomax
Journal:  Regen Med       Date:  2011-11       Impact factor: 3.806

4.  Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent.

Authors:  Justin Lowenthal; Scott Lipnick; Mahendra Rao; Sara Chandros Hull
Journal:  Stem Cells Transl Med       Date:  2012-05-08       Impact factor: 6.940

5.  Disclosure and management of research findings in stem cell research and banking: policy statement.

Authors:  Rosario Isasi; Bartha M Knoppers; Peter W Andrews; Annelien Bredenoord; Alan Colman; Lee Eng Hin; Sara Hull; Ock-Joo Kim; Geoffrey Lomax; Clive Morris; Douglas Sipp; Glyn Stacey; Jan Wahlstrom; Fanyi Zeng
Journal:  Regen Med       Date:  2012-05       Impact factor: 3.806

6.  Publishing SNP genotypes of human embryonic stem cell lines: policy statement of the International Stem Cell Forum Ethics Working Party.

Authors:  Bartha M Knoppers; Rosario Isasi; Nissim Benvenisty; Ock-Joo Kim; Geoffrey Lomax; Clive Morris; Thomas H Murray; Eng Hin Lee; Margery Perry; Genevra Richardson; Douglas Sipp; Klaus Tanner; Jan Wahlström; Guido de Wert; Fanyi Zeng
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

Review 7.  Return of results in translational iPS cell research: considerations for donor informed consent.

Authors:  Geoffrey P Lomax; Kelly A Shepard
Journal:  Stem Cell Res Ther       Date:  2013-01-21       Impact factor: 6.832

  7 in total
  11 in total

1.  Need for DISCUSS(ion).

Authors:  Mahendra S Rao
Journal:  Stem Cells Transl Med       Date:  2015-02       Impact factor: 6.940

Review 2.  Concise review: making and using clinically compliant pluripotent stem cell lines.

Authors:  Melissa K Carpenter; Mahendra S Rao
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

3.  Ethics and policy issues for stem cell research and pulmonary medicine.

Authors:  Justin Lowenthal; Jeremy Sugarman
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

Review 4.  The DISCUSS Project: Revised Points to Consider for the Derivation of Induced Pluripotent Stem Cell Lines From Previously Collected Research Specimens.

Authors:  Geoffrey P Lomax; Sara Chandros Hull; Rosario Isasi
Journal:  Stem Cells Transl Med       Date:  2015-01-05       Impact factor: 6.940

5.  Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.

Authors:  Peter W Andrews; Joy Cavagnaro; Joy Cavanagro; Robert Deans; Ellen Feigal; Ellen Feigel; Ed Horowitz; Armand Keating; Mahendra Rao; Marc Turner; Ian Wilmut; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 6.  Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative.

Authors:  Leonard A Levin; Joan W Miller; Donald J Zack; Martin Friedlander; Lois E H Smith
Journal:  Ophthalmology       Date:  2017-03-29       Impact factor: 12.079

Review 7.  Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors:  Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal:  Mol Cell Neurosci       Date:  2015-12-04       Impact factor: 4.314

Review 8.  Ethical issues in stem cell research and therapy.

Authors:  Nancy Mp King; Jacob Perrin
Journal:  Stem Cell Res Ther       Date:  2014-07-07       Impact factor: 6.832

Review 9.  Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease.

Authors:  Kyeong-Ah Kwak; Seung-Pyo Lee; Jin-Young Yang; Young-Seok Park
Journal:  Stem Cells Int       Date:  2018-03-01       Impact factor: 5.443

Review 10.  Donor information in research and drug evaluation with induced pluripotent stem cells (iPSCs).

Authors:  Marcin Orzechowski; Maximilian Schochow; Michael Kühl; Florian Steger
Journal:  Stem Cell Res Ther       Date:  2020-03-19       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.